{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:35:03Z","timestamp":1791952503806,"version":"4.3.4"},"reference-count":21,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>As cystic fibrosis (CF) lung disease progresses, the airways become infected with opportunistic pathogens, such as Pseudomonas aeruginosa (PA). In October 2019, the US Food and Drug Administration approved elexacaftor\/tezacaftor\/ivacaftor (ETI), a highly effective modulator therapy (HEMT), for individuals 12 years and older with 1 copy of the F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation. ETI increases the amount of and function of CFTR in the respiratory epithelium, improving mucociliary clearance and reducing static airway mucus, a major trigger for chronic infection and inflammation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>A retrospective analysis of inhaled tobramycin (iTOB) prescriptions between January 1, 2016, and December 31, 2021, was performed. This captured data before and after ETI approval at Children\u2019s Mercy Kansas City (CMKC). The number of individuals with new PA acquisition and individuals considered \u00adchronically infected was analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The number of eradication prescriptions declined in 2020 and 2021, with 15 (7%) and 12 (5%) \u00adindividuals prescribed therapy for those years, respectively. A similar pattern was observed for \u00adprescriptions for chronic infection. A reduction was seen in 2020 and 2021, with 28 (13%) and 20 (9%) individuals \u00adprescribed therapy for the respective years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The CMKC experienced a decrease in the number of courses of iTOB prescribed during the last 6 years. The reasons for this are likely multifactorial and may include the implementation of standardized PA surveillance and eradication protocols, the effect of HEMT on mucociliary clearance and airway microbiology, and the poorly understood effects of the SARS-CoV-2 pandemic on the epidemiology of respiratory infections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-29.2.135","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T17:22:36Z","timestamp":1712596956000},"page":"135-139","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on <i>Pseudomonas aeruginosa<\/i> Acquisition and Chronic Infection at a Single Pediatric Cystic Fibrosis Care Center"],"prefix":"10.5863","volume":"29","author":[{"given":"Stephanie","family":"Duehlmeyer","sequence":"first","affiliation":[{"name":"Departments of Pharmacy (SRD, ECE), Children\u2019s Mercy- Kansas City, Kansas City, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Claire","family":"Elson","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy (SRD, ECE), Children\u2019s Mercy- Kansas City, Kansas City, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Oermann","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics (CMO), Children\u2019s Mercy- Kansas City, Kansas City, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"2024040817222005800_i2331-348X-29-2-135-b01","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/bmj.39391.713229.AD","article-title":"Cystic fibrosis","volume":"335","author":"Davies","year":"2007","journal-title":"BMJ"},{"issue":"10","key":"2024040817222005800_i2331-348X-29-2-135-b02","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic Fibrosis Foundation pulmonary guideline: pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2024040817222005800_i2331-348X-29-2-135-b03","unstructured":"Cystic Fibrosis Foundation Patient Registry\n          . 2019Annual data report. Bethesda, Maryland. https:\/\/www.cff.org\/sites\/default\/files\/2021-10\/2019-Annual-Report.pdf. Accessed, March 25, 2022."},{"key":"2024040817222005800_i2331-348X-29-2-135-b04","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"2024040817222005800_i2331-348X-29-2-135-b05","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"2024040817222005800_i2331-348X-29-2-135-b06","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination in people homozygous for the F508del mutation: a double-blind, randomized, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2024040817222005800_i2331-348X-29-2-135-b07","author":"Trikafta [package insert]","year":"2021"},{"key":"2024040817222005800_i2331-348X-29-2-135-b08","unstructured":"US Food and Drug Administration\n          . FDA approves new breakthrough therapy for cystic fibrosis [press release]. October 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-breakthrough-therapy-cystic-fibrosis, accessed March 25, 2022."},{"issue":"1","key":"2024040817222005800_i2331-348X-29-2-135-b09","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"issue":"2","key":"2024040817222005800_i2331-348X-29-2-135-b10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2024040817222005800_i2331-348X-29-2-135-b11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024040817222005800_i2331-348X-29-2-135-b12","unstructured":"Cystic Fibrosis Foundation Patient Registry\n          . 2021Annual data report. Betheseda, Maryland. https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf. Accessed, March 25, 2022."},{"key":"2024040817222005800_i2331-348X-29-2-135-b13","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation","volume":"181","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"7","key":"2024040817222005800_i2331-348X-29-2-135-b14","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/jmv.26964","article-title":"Where have all the viruses gone?: disappearance of seasonal respiratory viruses during the COVID-19 pandemic","volume":"93","author":"Tang","year":"2021","journal-title":"J Med Virol"},{"issue":"12","key":"2024040817222005800_i2331-348X-29-2-135-b15","first-page":"2199","article-title":"Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter","volume":"72","author":"Yeow","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2024040817222005800_i2331-348X-29-2-135-b16","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1097\/INF.0000000000002845","article-title":"Effect of social distancing due to the COVID-19 pandemic on the incidence of viral respiratory tract infections in children in Finland during early 2020","volume":"39","author":"Kuitunen","year":"2020","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"2024040817222005800_i2331-348X-29-2-135-b17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/ppul.22917","article-title":"Respiratory viruses are associated with common respiratory pathogens in cystic fibrosis","volume":"49","author":"Esther","year":"2013","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"2024040817222005800_i2331-348X-29-2-135-b18","doi-asserted-by":"crossref","first-page":"e0164232","DOI":"10.1371\/journal.pone.0164232","article-title":"Throat swabs and sputum culture as predictors of P. aeruginosa or S. aureus lung colonization in adult cystic fibrosis patients","volume":"11","author":"Seidler","year":"2016","journal-title":"PLoS One"},{"key":"2024040817222005800_i2331-348X-29-2-135-b19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fped.2018.00403","article-title":"Respiratory bacterial culture sampling in expectorating and non-expectorating patients with cystic fibrosis","volume":"6","author":"Eyns","year":"2018","journal-title":"Front Pediatr"},{"issue":"5","key":"2024040817222005800_i2331-348X-29-2-135-b20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jcf.2016.01.001","article-title":"Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis","volume":"15","author":"Zampoli","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"5","key":"2024040817222005800_i2331-348X-29-2-135-b21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V","article-title":"Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis","volume":"28","author":"Rosenfeld","year":"1999","journal-title":"Pediatr Pulmonol"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/2\/135\/3354476\/i2331-348x-29-2-135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/2\/135\/3354476\/i2331-348x-29-2-135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:41:22Z","timestamp":1738780882000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/2\/article-p135.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,8]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.2.135","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}